title: In vitro mutagenicity and blood compatibility of paclitaxel and curcumin in poly (DL-lactide-co-glicolide) films.
abstract: Curcumin is considered to be a potential component for drug-eluting stents due to its anti-inflammatory properties. In this study we compared the mutagenicity and blood compatibility of curcumin to first generation drug eluting stent components: paclitaxel and sirolimus. The Ames test was used to assess mutagenicity. Blood compatibility was tested by measuring platelet activation and fibrinogen adsorption on poly (DL-lactide-co-glycolide, PLGA) films. We discovered that there was no significant increase in the number of revertants/plate following treatment with curcumin (up to 0.5mg/plate) or sirolimus (up to 0.5 μg/plate). However, a significant induction in the frequency of bacterial his(+) revertant colonies by paclitaxel at concentrations of 0.02, 0.05, 0.1, 0.2 and 0.5 μg/plate was observed. We also discovered a significant reduction in platelet activation by PLGA films containing 30% and 50% by weight curcumin. A similar reduction in platelet activation was also observed for PLGA films containing 1% by weight paclitaxel. In addition, we observed an increase of fibrinogen adsorption to PLGA-films containing curcumin. This would compromise the potential use of curcumin as a component of drug-eluting stents. Moreover, our data challenges the current view that paclitaxel does not significantly induce mutagenesis.
authors.affiliation: Department of Biochemistry and Molecular Biology, Biological Sciences Institute, Federal University of Goiás, Goiânia, GO, Brazil.
authors.forename: Iara Lucia Barbosa Fernandes
authors.initials: IL
authors.lastname: Vieira
authors.forename: Debora Cristina Passos
authors.initials: DC
authors.lastname: de Souza
authors.forename: Liliane
authors.initials: L
authors.lastname: da Silva Coelho
authors.forename: Lee Chen
authors.initials: LC
authors.lastname: Chen
authors.forename: Lidia Andreu
authors.initials: LA
authors.lastname: Guillo
mesh_terms: D000327:Adsorption; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000633:toxicity*; D003474:Curcumin / Q000008:administration & dosage / Q000633:toxicity*; D054855:Drug-Eluting Stents; D005340:Fibrinogen / Q000737:chemistry; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D009152:Mutagenicity Tests; D009153:Mutagens / Q000008:administration & dosage / Q000633:toxicity*; D017239:Paclitaxel / Q000008:administration & dosage / Q000633:toxicity*; D015539:Platelet Activation / Q000187:drug effects; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012485:Salmonella typhi / Q000187:drug effects / Q000235:genetics; D020123:Sirolimus / Q000008:administration & dosage / Q000633:toxicity
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D009153:Mutagens; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D005340:Fibrinogen; D003474:Curcumin; D017239:Paclitaxel; D020123:Sirolimus